Tapentadol Extended Release

[1]  Anthony K. P. Jones,et al.  Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol , 2012, Pain practice : the official journal of World Institute of Pain.

[2]  A. Sutton,et al.  Effect of Tapentadol Extended Release on Productivity: Results From an Analysis Combining Evidence From Multiple Sources , 2012, The Clinical journal of pain.

[3]  H. Liedgens,et al.  PSY31 Cost-Effectiveness of Tapentadol Prolonged-Release (Pr) Compared to Oxycodone Controlled Release (Cr) in Patients with Chronic Severe Non-Cancer Pain in Ireland , 2011 .

[4]  J. Kleijnen,et al.  Systematic review of tapentadol in chronic severe pain , 2011, Current medical research and opinion.

[5]  J. Goldberg,et al.  F644 AN ANALYSIS OF CHANGES IN VITAL SIGNS AND ELECTROCARDIOGRAM MEASUREMENTS WITH TAPENTADOL PROLONGED RELEASE (PR) TREATMENT , 2011 .

[6]  C. Hartrick,et al.  Tapentadol in Pain Management , 2011, CNS drugs.

[7]  J. Vry,et al.  Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  D. Biondi,et al.  A post hoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) versus oxycodone controlled release (CR) in patients ≥75 years of age , 2011 .

[9]  D. Biondi,et al.  A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies , 2011 .

[10]  S. Schwartz,et al.  Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial , 2010, Current medical research and opinion.

[11]  H. Liedgens,et al.  PSY34 COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN , 2010 .

[12]  B. Kuperwasser,et al.  337 HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL EXTENSION STUDY , 2010 .

[13]  C. Rauschkolb,et al.  A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. , 2010, International journal of clinical pharmacology and therapeutics.

[14]  J. Frampton.  Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. , 2010, Drugs.

[15]  C. Rauschkolb,et al.  Long‐term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain , 2010, Pain practice : the official journal of World Institute of Pain.

[16]  J. Vry,et al.  Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain , 2010, European journal of pain.

[17]  H. Kress.  Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally‐acting analgesics on the horizon? , 2010, European journal of pain.

[18]  C. Rauschkolb,et al.  Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study , 2010, Expert opinion on pharmacotherapy.

[19]  A. Okamoto,et al.  Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain , 2010, Advances in therapy.

[20]  C. Rauschkolb,et al.  292 TAPENTADOL PROLONGED RELEASE (PR) FOR PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN): EFFICACY AND SAFETY BY PRIOR OPIOID EXPERIENCE AND DOSE CATEGORY , 2010 .

[21]  D. Biondi,et al.  Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: influence of prior opioid experience on study discontinuations due to constipation, nausea, or vomiting , 2010 .

[22]  D. Biondi,et al.  Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: analyses of study discontinuations due to constipation, nausea, or vomiting , 2010 .

[23]  J. Smit,et al.  Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies , 2010, Pharmacotherapy.

[24]  J. Haeussler,et al.  707 ANALYSIS OF EFFICACY AND SAFETY OF TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN BASED ON PRIOR OPIOID EXPERIENCE , 2009 .

[25]  G. Pasternak,et al.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. , 2009, The journal of pain : official journal of the American Pain Society.

[26]  R. Chou,et al.  Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. , 2009, The journal of pain : official journal of the American Pain Society.

[27]  B. Dasgupta,et al.  Sarcoid sacroiliitis: successful treatment with infliximab , 2009, Annals of the rheumatic diseases.

[28]  K. Schiene,et al.  (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  Iris Pigeot,et al.  Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design , 2005, Biometrical journal. Biometrische Zeitschrift.

[30]  J. Foss,et al.  Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects? , 2004, Anesthesia and analgesia.

[31]  B. Nicholson.  Responsible Prescribing of Opioids for the Management of Chronic Pain , 2012, Drugs.

[32]  C. Rauschkolb,et al.  Dose conversion between tapentadol immediate and extended release for low back pain. , 2010, Pain physician.

[33]  M. Afilalo,et al.  Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee , 2010, Clinical drug investigation.

[34]  C. Rauschkolb,et al.  Health-related outcomes associated with tapentadol extended release (ER) treatment for the management of painful diabetic peripheral neuropathy (DPN): results of a randomized-withdrawal phase 3 trial , 2009 .

[35]  A. Okamoto,et al.  Health status (EuroQol-5 Dimension [EQ-5D]) in patients with painful diabetic peripheral neuropathy (DPN) treated with tapentadol extended release (ER): results of a randomized-withdrawal phase 3 study , 2009 .